Atea Pharmaceuticals, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Atea Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $871.00K.
- Atea Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $58.00K.
- Atea Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for the quarter ending 2022-09-30 was $7.00K, a 99.12% decline year-over-year.
- Atea Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for the quarter ending 2022-03-31 was $223.00K, a 52.65% decline year-over-year.
- Atea Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $58.00K.
- Atea Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $230.00K, a 84.30% decline from fiscal 2021.
- Atea Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for fiscal 2021 was $1.47M, a 5325.93% increase from fiscal 2020.
- Atea Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for fiscal 2020 was $27.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-03-31 | $871.00K 10-Q · filed 2026-08-12 | |
| 2025-12-31 | $58.00K 10-K · filed 2026-03-05 | |
| 2025-09-30 | $58.00K 10-Q · filed 2025-11-12 | |
| 2022-12-31 | $230.00K 10-K · filed 2024-02-28 | |
| 2022-09-30 | $7.00K 10-Q · filed 2023-11-08 | |
| 2022-03-31 | $223.00K 10-Q · filed 2023-11-08 | |
| 2021-12-31 | $1.47M 10-K · filed 2023-02-28 | |
| 2021-09-30 | $795.00K 10-Q · filed 2022-11-07 | |
| 2021-06-30 | $57.00K 10-Q · filed 2022-11-07 | |
| 2021-03-31 | $471.00K 10-Q · filed 2022-11-07 | |
| 2020-12-31 | $27.00K 10-K · filed 2023-02-28 | |
| 2020-06-30 | $27.00K 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |